David L. Gillespie, PhD

Journal Article

1. Towner RA, Gillespie DL, Schwager A, Saunders DG, Smith N, Njoku CE, Krysiak RS 3rd, Larabee C, Iqbal H, Floyd RA, Bourne DW, Abdullah O, Hsu EW, Jensen RL (2013 Mar). Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007. Neuro Oncol.
2. Towner RA, Jensen RL, Colman H, Vaillant B, Smith N, Casteel R, Saunders D, Gillespie DL, Silasi-Mansat R, Lupu F, Giles CB, Wren JD (2012 Oct 23). ELTD1, A Potential New Biomarker for Gliomas. Neurosurgery.
3. James K Liu, Smruti K Patel, David L Gillespie, Kum Whang, William T Couldwell (09/2011). R-flurbiprofen, a novel nonsteroidal anti-inflammatory drug, decreases cell proliferation and induces apoptosis in pituitary adenoma cells in vitro. J Neurooncol, 106(3)(56), 1-9.
4. Yinni Yu, Steve Blair, David Gillespie, Randy Jensen, David G Myszka, Ahmed HBadran, Indraneel Ghosh, and Alexander Chagovetz (2010 June 15). Direct DNA Methylation Profiling Using Methyl Binding Domain Proteins. Anal Chem, 82(12), 5012–5019.
5. Wang XL, Xu R, Xu X, Gillespie D, Jensen RL, Lu ZR (2009). Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice. Mol Pharm, 6(3), 738-746.
6. Gillespie DL, Flynn JR, Ragel BT, Arce-Larreta M, Kelly DA, Tripp SR, Jensen RL (2008). Silencing of HIF-1a by RNA interference in human glioma cells in vitro and in vivo. Methods Mol Biol, 487, 283-301.
7. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, Ellsworth GB, Salzman KL, Kinney AY, Jensen RL (2008). Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer, 113(5), 1032-1042.
8. Ragel BT, Couldwell WT, Gillespie DL, Wendland MM, Whang K, Jensen RL (2008). A comparison of the cell lines used in meningioma research. Surg Neurol, 70, 295–307.
9. Ragel BT, Elam IL, Gillespie DL, Flynn JR, Kelly DA, Mabey D, Feng H, Couldwell WT, Jensen RL (2008). A novel model of intracranial meningioma in mice using luciferase-expressing meningioma cells. Laboratory investigation. J Neurosurg, 108(2), 304-310.
10. Wang XL, Thanh N, Gillespie D, Jensen R, Lu ZR (2007). A novel multifunctional and reversibly polymerizable carrier for efficient siRNA delivery. Biomaterials, 29(1), 12-22.
11. Ragel BT, Couldwell WT, Gillespie DL, Jensen RL (2007). Identification of hypoxia-induced genes in a malignant glioma cell line (U-251) by cDNA microarray analysis. Neurosurg Rev, 30(3), 181-7; discussion 187. (Read full article)
12. Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA, Jensen RL (2007). Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res, 13(8), 2441-8. (Read full article)
13. Ragel B, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT (2007). Celecoxib inhibits meningioma tumor growth in the mouse xenograft model. Cancer, 109(3), 588-597.
14. Ragel BT, Gillespie DL, Kushnir V, Polevaya N, Kelly D, Jensen RL (2006). Calcium channel antagonists augment hydroxyurea and RU486-induced inhibition of meningioma growth in vivo and in vitro. Neurosurgery, 59(5), 1109-1121.
15. Jensen RL, Ragel BT, Whang K, Gillespie D (2006). Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol, 78(3), 233-47.
16. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT (2005). Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application. J Neurosurg, 103(3), 508-17. (Read full article)
17. Jensen RL, Gillespie D, House P, Layfield L, Shelton C (2004). Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor 1alpha expression. J Neurosurg, 100(3), 488-97.